Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Operator: Greetings, and welcome to the Personalis, Inc. First Quarter 2026 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, as a reminder, this conference is being recorded. It is now my pleasure to introduce Caroline Corner of Investor Relations. Thank you, and you may proceed, Caroline. Caroline V. Corner: Thank you, operator. Welcome to Personalis, Inc.'s first quarter 2026 earnings call. Joining today's call are Christopher M. Hall, Chief Executive Officer; Aaron L. Tachibana, Chief Financial and Chief Operating Officer; and Richard Chen, President and Chief Medical Officer. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of U.S. securities laws, including any statements regarding trends and expectations for our financial performance this year and longer term, cash runway and liquidity position, revenue expectations and timing, size and booking of orders, products, services, technology, expansion of clinical volume, reimbursement goals, the outcome and timing of reimbursement decisions, expectations for our existing and future collaboration activities, cost expectations, market size and our market opportunity, and business outlook. These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations. We encourage you to review our recent filings, including the risk factors described in our most recent filings. Personalis, Inc. undertakes no obligation to update these statements, except as required by applicable law. Our press release with our first quarter 2026 results is available on our website, wwwpersonnel.com, under the investors section and includes additional details about our financial results. Our website also has our latest SEC filings, which we encourage you to review. A recording of today's call will be available on our website by 5:00 PM Pacific Time today. With that, I would like to turn the call over to Chris. Christopher M. Hall: Good afternoon, everyone. Thank you for joining us. I am incredibly proud of what our team has accomplished in this first quarter, and more importantly, I am energized by where we are going. Since we launched NeXT Personal, we have not just validated our win-in-MRD strategy; we have disrupted the market. Last year in 2025, we established the power of our platform, and this year in 2026, we are scaling it. We are squarely focused on driving volume in this large and rapidly expanding market. Physicians trust NeXT Personal, our clinical test volumes are accelerating, and the broader medical community is validating our roadmap. For those of you new to our story, Personalis, Inc. is changing how cancer recurrence is detected and monitored. We operate at the …
Est. EPS $-0.26 · Revenue $21.54M · 3 analysts
Est. EPS $-0.25 · Revenue $24.97M · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Christopher Hall | CEO & Director | USD 868,200 | Male | 1969 | Active |
Aaron L. Tachibana | Chief Financial Officer & Chief Operating Officer | USD 679,900 |
| Male |
| 1961 |
| Active |
Richard Chen | President & Chief Medical Officer | USD 660,750 | — | 1971 | Active |
Stephen Moore | Senior Vice President, Chief Legal Officer & Corporate Secretary | USD 597,975 | Male | 1972 | Active |
Deepshikha Bhandari | Senior Vice President of Regulatory, Quality & Clinical Compliance | — | Female | — | Active |
Stephane Mouradian | Senior Vice President of Business Development | — | Male | — | Active |
Christian Haudenschild | Senior Vice President of Genomic Science | — | — | — | Active |
Michael Snyder | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | — | Active |
Russ Altman | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | — | Active |
Ashish Kheterpal | Senior Vice President & Chief Information Officer | — | Male | — | Active |
Euan A. Ashley DPHIL FRCP | Co-Founder and Member of Clinical & Scientific Advisory Board | — | — | 1971 | Active |
Est. EPS $-1.08 · Revenue $80.87M · 3 analysts
Est. EPS $-0.25 · Revenue $20.83M · 1 analysts
EPS $-0.18 · Revenue $20.61M
| $69.6M |
| -17.7% |
| +44.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-81.3M | +0.0% | -5.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +22.7% | -28.5% | +1068.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -126.4% | -56.7% | +27.7% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -116.7% | -21.5% | +27.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-79.5M | -69.9% | -15.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -114.1% | -106.5% | +20.3% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 15.3% | -29.8% | +6.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.76x | +3.7% | -20.1% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $334.2M | +23.6% | -4.1% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.91 vs -0.94 | +3.0% | -0.30 vs -0.26 | -14.5% |
| Revenue Surprise | $69.6M vs $69.5M | +0.2% | $22.4M vs $21.5M | +3.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | Chen Richard | officer: President and CMO | Common Stock | A | 100,000 | $2.44 |
| Jul 15, 2026 | Chen Richard | officer: President and CMO | Common Stock | D | 100,000 | $15.15 |
| Jul 15, 2026 | Chen Richard | officer: President and CMO | Stock Option (right to buy) | D | 100,000 | $2.44 |
| Jul 9, 2026 | Hall Christopher M | director, officer: Chief Executive Officer | Common Stock | A | 100,000 | $1.61 |
| Jul 9, 2026 | Hall Christopher M | director, officer: Chief Executive Officer | Common Stock | D | 100,000 | $15.08 |
